New FDA Rule Aims To Give More Flexibility To Foreign Trials
Executive Summary
In response to a five-year-old congressional mandate, the US agency has updated a rule and issued a companion guidance that would allow more flexibility for sponsors conducting studies outside the United States.
You may also be interested in...
US FDA Now Requires GCP Statement For Foreign Trial Data
A regulation finalized last year kicks in today requiring companies to either include along with US FDA submissions a statement affirming Good Clinical Practice compliance for any data collected outside the US, or get a waiver.
FDA's US-First Strategy: Device Center Sets Three-Year Goals
A new three-year plan to implement strategic priorities at US FDA's device center aims to make several broad improvements to the medtech ecosystem. Among them is improving staff incentives at the agency, creating more partnerships with industry and other stakeholders, and improving the center's processes to make it easier for novel medical devices to enter the US market.
Massive Family Dollar Rat Infestation Leads To Multi-State Recall
The US FDA found more than 2,000 rats at an Arkansas Family Dollar distribution center, leadingto a six-state recall for products including feminine hygiene products, contact lens cleaners and face masks.